FDA rejects Merck's Cordaptive

Share this article:
The FDA has issued Merck a not approvable letter regarding its developmental cholesterol-lowerer dubbed Cordaptive.

Regulators have also rejected the brand name of Cordaptive for the drug, which is also known as Mk-0524a. The drug is a combination of good-cholesterol raising vitamin niacin and laropiprant, a drug designed to lessen the facial flushing caused by niacin.

Merck said it plans to meet with the agency to provide additional data and further examine the drug's benefit-risk profile. 

Merck planned to package Cordaptive with its treatment Zocor, a $5 billion-a-year blockbuster before losing patent protection in 2006.

The failure of Cordaptive “comes as a surprise, given the publicly disclosed data,'' said Deutsche Bank analyst Barbara Ryan in a note to investors today. “Without more information, it is difficult to gauge what the FDA took issue with, or what additional data Merck could provide to gain approval.”
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.